At­las, F-Prime launch K36 Ther­a­peu­tics to ad­vance on­col­o­gy mol­e­cule for elu­sive epi­ge­net­ic tar­get

Af­ter be­ing in stealth for near­ly 11 months, a new biotech has made it­self known, com­plete with an in­flux of cash from some big-name in­vestors.

K36 Ther­a­peu­tics, an on­col­o­gy biotech out of Cam­bridge, MA, emerged from stealth this morn­ing — an­nounc­ing a long-fin­ished $30M Se­ries A co-led by F-Prime Cap­i­tal, At­las Ven­ture and glob­al in­vest­ment firm Eight Roads Ven­tures.

K36 CEO Ter­ry Con­nol­ly told End­points News that the se­ries was ac­tu­al­ly closed back in Feb­ru­ary — and is now just be­ing an­nounced. Con­nol­ly said that he ex­pects the fund­ing to get K36 through proof-of-con­cept stud­ies and hope­ful­ly push the can­di­date to the IND phase, which the biotech plans to file by the end of June next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER